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 IMRT  ARC  
 Median (Range) Median (Range) p 
Eye L maximum dose (Gy)  12.36 (8.30-15.70) 14.86 (13.22-17.73)  <0.05 
Eye L mean dose (Gy)  5.34 (4.42-6.40) 7.83 (7.27-9.66)  <0.05 
Eye R maximum dose (Gy)  11.53 (7.20-14.94)  14.81 (13.85-17.35) <0.05 
Eye R mean dose (Gy) 5.91 (4.33-6.60) 7.97 (7.66-9.02) <0.05 
Monitor Unit 2076 (1759-2201) 617 (584-695) <0.001 
 
Conclusion: Non-coplanar IMRT is superior to coplanar VMAT 
in sparing eye without of any worse results on targets. But, 
negative aspects of non-coplanar IMRT technique such as 
duration of treatment as a result of high MU values, can 
affect significantly negative in routine practice. 
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Purpose or Objective: This study investigated conformation 
number (CN), homogeneity index (HI), and doses to heart, 
ipsilateral lung, contralateral lung and breast from two 
distinct radiotherapy techniques for early left-sided breast 
cancer patients after lumpectomy. We compared volumetric 
modulated arc therapy (VMAT) and field-in-field (FiF). Both 
technique utilized hypofractionation with simultaneous 
integrated boost (SIB). 
 
Material and Methods: From archival CT scans, we selected 7 
situations: 4 tumor locations in upper-outer quadrant (the 
most common), 1 in upper-inner quadrant, 1 in lower-outer 
quadrant, and 1 in lower-inner quadrant. SIB provided 
differential dosing to the whole breast and the resection 
cavity at each fraction; hence reduced the number of 
treatment fractions. In both VMAT and FiF, fractionation 
schemes were 28 daily fractions of 1.8 Gy to the whole breast 
and 2.15 Gy to the tumor bed adding up to a total dose of 
60.2 Gy. They were biologically equivalent to the sequential 
boost-technique comprising 25 fractions of 2 Gy to the whole 
breast PTV followed by a boost irradiation in 6 fractions, 
using an alpha/beta ratio of 4 Gy for tumor response, based 
on the linear-quadratic cell survival model. Planning target 
volume (PTV)-breast and PTV-boost were defined by 
expanding whole breast isotropically by 5 mm and 3 mm, 
respectively. Dose volume constraints for ipsilateral lung: 
V20Gy < 20%, V5Gy < 40%; for contralateral lung: V5<5%; for 
contralateral breast: mean dose <3 Gy; for the heart: mean 
dose<10Gy and V20Gy < 15%. The goal was to encompass the 
PTV in all direction with the 95% isodose line, and volumes 
receiving higher than 110% of the prescribed dose were 
minimized. One experienced VMAT planner developed all 
VMAT plans while the other experienced FiF planner 
developed all FiF plans. The optimal CN is 1 since 
CN=(TV95%/TV)x(TV95%/V95%). The optimal HI is 0 since 
HI=(D2%-D98%)/D. CN, HI, and doses to normal tissues were 
compared by the Wilcoxon signed-rank test. 
 
Results: VMAT significantly improved both CN for PTV-boost 
(0.66 vs. 0.29) and PTV-breast (0.82 vs 0.55), HI for PTV-
breast (25.01 vs 32.54), mean dose to heart (4.08 vs 7.71), 
V20-heart (3.14 vs 13.12), V20-left lung (11.49 vs 24.29) and 
V5-left lung (31.54 vs 35.98), p = 0.018. The mean healthy 
breast dose was similar between VMAT and FiF (2.39 and 1.68 
Gy, respectively); and the HI for PTV-Boost was also similar 
between VMAT and FiF (10.95 and 13.72, respectively). 
However, FiF did better in sparing contralateral lung. The 
mean dose to contralateral lung by VMAT and FiF were 1.75 
Gy vs 0.46 Gy, respectively (p = 0.018). 
 
Conclusion: VMAT significantly improved conformity and 
homogeneity in hypofractionated SIB plans for breast cancer. 
Doses to heart and ipsilateral lung were significantly 
decreased, yet more contralateral lung received low doses 
that less than 2 Gy averagely. Doses to contralateral breast 
showed no difference between VMAT and FiF. 
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Purpose or Objective: To develop a volumetric arc therapy 
(VMAT) technique for delivering Total Marrow Irradiation 
(TMI) treatments at this institution using RapidArc™; to assess 
its benefits over the standard parallel-opposed technique, 
and evaluate the feasibility of delivering it. 
 
Material and Methods: 5 previously treated TMI patients 
were retrospectively planned with RapidArc™. The 
treatments were delivered as quality assurance (QA) plans 
and verified using the Octavius™ phantom and PTW™ 2D 
array. The conventional parallel-opposed technique was 
modelled in the Eclipse™ Treatment Planning System and the 
dose distributions compared with the RapidArc™ plans. 
 
Results: The VMAT plans were highly conformal, 
demonstrating significant dose reductions to organs at risk 
(OAR). The average median dose to the OARs with VMAT was 
5.4Gy±1.3 and ranged from 2.8Gy in the oral cavity to 8.1Gy 
in the spleen. These are gains of between 25% and 73% 
compared to the conventional parallel-opposed technique 
which had an average median dose of 11.6±0.2. Target 
coverage was similar between the two plans with a D99 of 
10.7Gy±0.4 for conventional TMI and 10.8±0.2Gy for VMAT 
TMI. The VMAT TMI plans had slightly higher global maximums 
than the parallel opposed plans: 13.6Gy±0.1 for VMAT; 
12.6Gy±0.4 for parallel-opposed. The plan verification 
showed good agreement between the Eclipse distributions 
and measured data. The study gamma analysis pass rate 
averaged 99.0 ± 0.5 for all anatomical regions and plans. 
 
 
 
Conclusion: VMAT planning for TMI has the potential to 
significantly reduce doses to OARs, thereby increasing the 
therapeutic ratio, and giving the potential for dose 
escalation. The verification process confirmed good 
agreement between calculated and measured data. VMAT TMI 
is a technically feasible alternative to the standard TMI 
technique but further evaluation is required before clinical 
implementation. 
 
 
 
